key: cord-1047079-xhl4qme0
authors: Renaud, Felten; Marion, Geoffroy; Loïs, Bolko; Pierre-Marie, Duret; Marie, Desmurs; Angélique, Fan; Marion, Couderc; Laurent, Messer; Marc, Ardizzone; Ahmed, Yahia Samira; Rose-Marie, Javier; Alain, Meyer; Emmanuel, Chatelus; Christelle, Sordet; Luc, Pijnenburg; Jean, Sibilia; Martin, Soubrier; Jacques-Eric, Gottenberg; Jean-Hugues, Salmon
title: Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritides
date: 2022-04-28
journal: Joint Bone Spine
DOI: 10.1016/j.jbspin.2022.105391
sha: e174fd20d4a157ea7748cd6d184ea1533dee233a
doc_id: 1047079
cord_uid: xhl4qme0

nan

remain concerns about a reduced vaccine response in patients treated by immunosuppressive therapies [1] [2] [3] . We analysed the impact of bDMARDs on the humoral anti-SARS-CoV-2 vaccine response, after a vaccine regimen of 2 or 3 doses of vaccine, of patients followed in day hospitals, treated with an intravenous bDMARD between September 2019 and August 2021. The study was approved by the ethic review board of Strasbourg medical faculty (#CE-2021-103). Serological assessment was performed using various commercially available assays dosing IgG (or total) anti-Spike antibodies, all FDA approved [4] . Patients were considered non-responders if the antibody level detected was inferior to the threshold of positivity of the kit used.

205 patients were included. Characteristics and comparisons of responders and non-responders are summarized in Table 1 Our results illustrate the weaker anti-SARS-CoV-2 vaccine response in patient treated with B

or T-cell targeting treatments than in those treated with anti-cytokine biologicals (IFX and TCZ). The present study confirms that the time interval between the prevaccination administration of rituximab and vaccination has a significant impact on the vaccine's immunogenicity [5] [6] [7] but 4 months appear to be often insufficient. Indeed, 9 months between last rituximab infusion were necessary to obtain a serological response in only half of the patients.

The role of ABA in the reduced SARS-CoV-2 vaccine response, has not been studied extensively, as that of rituximab [1, 2, 8, 9] , despite a reduced vaccine response to other vaccines [10] , in agreement with the inhibitory effect of abatacept on T-cell costimulation. In the present study, median delay between last ABA infusion and the first dose of vaccine was longer than recommended (4 weeks) and no difference was shown according to the delay between last infusion and first dose of vaccine.

In conclusion, B-and T-cell targeted therapies were associated with nearly all vaccine nonresponses in the present study. 

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity

Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab

SARS CoV-2 vaccine AND rituximab, timing might be a key for a better vaccine response

Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy

Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis